In Brief Broad Institute, Dana-Farber, and Count Me In receive $16 million to launch patient-partnered research initiatives in rare cancers February 19, 2021Vol.47 No.07
In Brief Biden administration: Work requirements in Medicaid do not promote the objectives of the program February 19, 2021Vol.47 No.07
In Brief George Mason, Rutgers Cancer Institute collaboration receives $1.33M U.S. Army’s Breakthrough Award February 19, 2021Vol.47 No.07
Conversation with The Cancer Letter Lori Pierce: Therapies are of no use when patients can’t get off work to be treated February 19, 2021Vol.47 No.07By Robert A. Winn
Conversation with The Cancer LetterCOVID-19 & Cancer Antoni Ribas: Cancer research has been pivotal to development of COVID-19 vaccines February 19, 2021Vol.47 No.07By Alexandria Carolan
Guest Editorial Moffitt Cancer Center: Why we are building the first machine learning department in oncology February 19, 2021Vol.47 No.07By Issam El Naqa and Dana Rollison
Drugs & Targets Ukoniq receives FDA accelerated approval for marginal zone lymphoma and follicular lymphoma February 12, 2021Vol.47 No.06
Drugs & Targets Breyanzi receives FDA approval for adults with relapsed or refractory large-B-cell lymphoma February 12, 2021Vol.47 No.06
Drugs & Targets Libtayo receives FDA approval as first immunotherapy for patients with advanced basal cell carcinoma February 12, 2021Vol.47 No.06
Drugs & Targets MD Anderson, Mirati Therapeutics collaborate on KRAS and solid tumor research February 12, 2021Vol.47 No.06
